Immunogenicity

News Immunogenicity

• SEEK announces clinical proof of efficacy in HIV vaccine Phase Ib/II human trial

  SEEK, a privately owned biopharmaceutical company specializing in immunology, announced that it has completed a Phase Ib/II clinical trial of its HIV-v vaccine which demonstrates a one log (approx 90 percent) difference in viral count in HIV-infected people compared with the placebo group, after jus more

• Chris Beaver joins Pharmanet as Director, Immunochemistry Services

  PharmaNet Development Group, Inc. announced that Chris Beaver, PhD has joined the Company as Director, Immunochemistry Services. Dr. Beaver is responsible for leading the immunochemistry team within the Company’s bioanalytical laboratories and expanding its large molecule services, including assay more

• Intercell announces initial results of Phase II clinical trial evaluating V710, an investigational Staphylococcus aureus vaccine

  Intercell AG announced top-line results from a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infections. The study, conducted by Intercell's collaborator, a subsidiary of Merck & Co., Inc, was designed to evaluate the safety and i more

White papers Immunogenicity

• Characterizing Biotherapeutics with HPLC
  

  As demonstrated here, there are a broad range of HPLC applications used in development, production, validation and release of protein therapeutics for human use. Some of the applications mentioned above are mandatory when submitting a new biopharmaceutical to approval at the regulatory agencies. The introduction of the first so-called biosimilars in Europe further increased the demand for highly efficient analysis methods. The continuous development of new stationary phases for the common modes of biochromatography, such as size exclusion, ion exchange and hydrophilic interaction chromatography support biochemists in increasing lab productivity and establishing high-throughput HPLC analysis not only for small molecules but also for large biopolymers more

Publications Immunogenicity

• Dendritic cell immunotherapy

  The U.S. Food and Drug Administration's approval of the first cell‐based immunotherapy has rejuvenated interest in the field. Early clinical trials have established the ability of dendritic cell (DC) immunotherapy to exploit a patient's own immune system to induce antitumor immune responses. Howev more

• Identification of Oxidation Sites and Covalent Cross-Links in Metal Catalyzed Oxidized Interferon Beta-1a: Potential Implications for Protein Aggregation and Immunogenicity

  Oxidation via Cu2+/ascorbate of recombinant human interferon beta-1a (IFNβ1a) leads to highly immunogenic aggregates, however it is unknown which amino acids are modified and how covalent aggregates are formed. In the present work we mapped oxidized and cross-linked amino acid residues in aggregated more

• A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls

  by Eve Draper, Sara L. Bissett, Rebecca Howell-Jones, Pauline Waight, Kate Soldan, Mark Jit, Nicholas Andrews, Elizabeth Miller, Simon Beddows Background The current generation of Human Papillomavirus (HPV) vaccines, Cervarix® and Gardasil®, exhibit a high degree of efficacy in clinical trials ag more

Market studies Immunogenicity

• Pacific Biomarkers, Inc. (PBMC) - Financial and Strategic SWOT Analysis Review

  Pacific Biomarkers, Inc. (PBI) is a publicly held US-based healthcare service provider company. The company is principally engaged in providing specialty central laboratory and contract research services to support pharmaceutical and laboratory diagnostic producers in human clinical trial research. more

Websites Immunogenicity